Accelerate Diagnostics Inc (AXDX) USD0.001

Sell:$1.24Buy:$1.38$0.01 (0.76%)

Prices delayed by at least 15 minutes
Sell:$1.24
Buy:$1.38
Change:$0.01 (0.76%)
Prices delayed by at least 15 minutes
Sell:$1.24
Buy:$1.38
Change:$0.01 (0.76%)
Prices delayed by at least 15 minutes

Company Information

About this company

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.

Key people

John Phillips
President, Chief Executive Officer, Director
David Patience
Chief Financial Officer
Lawrence Michael Mertz
Chief Technology Officer
Hany Massarany
Independent Chairman of the Board
Mark Black
Independent Director
Wayne C. Burris
Independent Director
Louise L. Francesconi
Independent Director
Marran H. Ogilvie
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Technology
  • Industry
    Scientific & Technical Instr.
  • ISIN
    US00430H2013
  • Market cap
    $33.06m
  • Employees
    134
  • Shares in issue
    25.04m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.